Published in Mol Ther on September 11, 2007
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One (2008) 1.67
Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer. PLoS One (2015) 1.43
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules (2009) 1.35
The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem (2009) 1.25
Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther (2010) 1.23
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther (2009) 1.21
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines (2009) 1.08
Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther (2011) 1.07
Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther (2008) 1.01
Comparison of silk-elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery. Int J Pharm (2011) 0.91
Stealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X. Acta Biomater (2015) 0.90
PEGylated Adenoviruses: From Mice to Monkeys. Viruses (2010) 0.89
Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials (2011) 0.87
Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine. Mol Pharm (2013) 0.84
Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol Ther (2011) 0.83
VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol (2014) 0.83
A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Hum Gene Ther (2011) 0.83
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut (2014) 0.82
Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. Virus Genes (2017) 0.82
Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus. Int J Nanomedicine (2012) 0.81
Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo. PLoS One (2014) 0.77
TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall. Mol Ther (2017) 0.76
miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens. Mol Ther (2011) 0.76
Polymeric oncolytic adenovirus for cancer gene therapy. J Control Release (2015) 0.76
SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell (2008) 5.68
Evidence for a functional second thymus in mice. Science (2006) 2.54
Commensal gut flora drives the expansion of proinflammatory CD4 T cells in the colonic lamina propria under normal and inflammatory conditions. J Immunol (2008) 2.50
Contributions of host and symbiont pigments to the coloration of reef corals. FEBS J (2007) 1.55
The transcription factor serum response factor stimulates axon regeneration through cytoplasmic localization and cofilin interaction. J Neurosci (2013) 1.50
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med (2010) 1.45
Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther (2007) 1.43
Specific, functional effector/memory CD8+ T cells are found in the liver post-vaccination. J Hepatol (2003) 1.43
Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation. Hepatology (2012) 1.40
Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther (2003) 1.40
Adenoviral vectors for gene transfer and therapy. J Gene Med (2004) 1.31
Foxp3-expressing CD103+ regulatory T cells accumulate in dendritic cell aggregates of the colonic mucosa in murine transfer colitis. Am J Pathol (2006) 1.27
Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther (2010) 1.23
Hepatic dendritic cell subsets in the mouse. Eur J Immunol (2004) 1.22
A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther (2003) 1.22
Pseudoachondroplasia is caused through both intra- and extracellular pathogenic pathways. J Clin Invest (2002) 1.20
Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther (2005) 1.16
Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol (2005) 1.16
NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol (2003) 1.14
The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther (2008) 1.12
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood (2002) 1.11
A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther (2002) 1.10
Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology (2004) 1.09
Translation from cryptic reading frames of DNA vaccines generates an extended repertoire of immunogenic, MHC class I-restricted epitopes. J Immunol (2005) 1.09
Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur J Immunol (2003) 1.09
Accelerated aging phenotype in mice with conditional deficiency for mitochondrial superoxide dismutase in the connective tissue. Aging Cell (2010) 1.09
Chromosomal integration of adenoviral vector DNA in vivo. J Virol (2010) 1.07
Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1. Cancer Res (2007) 1.00
IL-20 receptor 2 signaling down-regulates antigen-specific T cell responses. J Immunol (2009) 1.00
Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol (2004) 0.99
Human cytomegalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral immunity. J Virol (2013) 0.98
Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol (2002) 0.98
B7-H1 on hepatocytes facilitates priming of specific CD8 T cells but limits the specific recall of primed responses. Gastroenterology (2008) 0.98
AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignancies. Blood (2005) 0.98
Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector. Invest Ophthalmol Vis Sci (2002) 0.98
Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol (2002) 0.97
IL-22-dependent attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J Immunol (2009) 0.97
High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther (2007) 0.97
Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential. J Immunol (2009) 0.96
Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7.1 mice. Diabetes (2002) 0.95
Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther (2010) 0.95
Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells. Eur J Immunol (2002) 0.95
Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology (2010) 0.94
Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther (2006) 0.94
Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade. Mol Ther (2004) 0.93
Real-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks. Genes Dev (2013) 0.93
Adenovirally transduced bone marrow stromal cells differentiate into pigment epithelial cells and induce rescue effects in RCS rats. Invest Ophthalmol Vis Sci (2006) 0.93
Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun (2010) 0.92
Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J Virol (2008) 0.92
Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J Mol Med (Berl) (2003) 0.91
Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther (2010) 0.91
Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes (2010) 0.91
Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol (2003) 0.91
The hepatic immune system. Crit Rev Immunol (2002) 0.90
Host gene expression in the colon of gnotobiotic interleukin-2-deficient mice colonized with commensal colitogenic or noncolitogenic bacterial strains: common patterns and bacteria strain specific signatures. Inflamm Bowel Dis (2006) 0.90
Long-term IKK2/NF-κB signaling in pancreatic β-cells induces immune-mediated diabetes. Diabetes (2013) 0.90
Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells. J Immunol (2002) 0.89
The diabetogenic, insulin-specific CD8 T cell response primed in the experimental autoimmune diabetes model in RIP-B7.1 mice. Eur J Immunol (2007) 0.89
Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur J Immunol (2003) 0.89
Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1. J Gene Med (2008) 0.87
Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med (2008) 0.87
Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector. Mol Ther (2002) 0.87
Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. Hepatology (2006) 0.87
Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications. Hum Gene Ther (2010) 0.87
A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit. Mol Vis (2008) 0.86
Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol (2002) 0.86
Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen. Eur J Immunol (2003) 0.86
Distinct, cross-reactive epitope specificities of CD8 T cell responses are induced by natural hepatitis B surface antigen variants of different hepatitis B virus genotypes. J Immunol (2006) 0.85
Colitogenic and non-colitogenic commensal bacteria differentially trigger DC maturation and Th cell polarization: an important role for IL-6. Eur J Immunol (2006) 0.85
Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol Ther (2008) 0.85